Rituximab: MS Clinical Trials
6 active trials · 3 recruiting
6 active multiple sclerosis clinical trials involve Rituximab, 3 currently recruiting. The list is matched on the interventions registered at ClinicalTrials.gov, so it includes head-to-head comparisons and studies where this therapy is the comparator as well as the treatment under test.
Trial results are not treatment advice: whether a therapy is right for you depends on your type of MS, disease activity and history, which is a conversation for your neurologist.
Active Rituximab MS trials
RecruitingPhase 2
The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
Sponsor: Cairo University
Rituximab · Saline (NaCl 0,9 %) (placebo)
46 participantsDetails ›
RecruitingPhase 3
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
Sponsor: Rennes University Hospital
Perfusion of treatment Rituximab · Perfusion of treatment Ocrelizumab
386 participantsDetails ›
RecruitingPhase 3
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Sponsor: Amsterdam UMC, location VUmc
Rituximab
200 participantsDetails ›
Closed to new patientsNA
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Sponsor: Johns Hopkins University
Natalizumab/natalizumab-sztn, Alemtuz… · Glatiramer acetate, Interferons (intr…
28 states900 participantsDetails ›
Closed to new patientsPhase 3
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
Sponsor: Rigshospitalet, Denmark
Rituximab · Ocrelizumab
600 participantsDetails ›
Closed to new patientsPhase 3
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease
Sponsor: Haukeland University Hospital
Rituximab · Ocrelizumab
214 participantsDetails ›
MS trials by therapy
Exercise and rehabilitation (81)Ocrelizumab (Ocrevus) (34)Ofatumumab (Kesimpta) (18)Diet and nutrition (12)Teriflunomide (Aubagio) (9)Fingolimod (Gilenya) (8)Ublituximab (Briumvi) (7)Cladribine (Mavenclad) (7)Ozanimod (Zeposia) (6)Dimethyl fumarate (Tecfidera) (6)Interferon beta (5)Fenebrutinib (5)Stem cell therapy (aHSCT and MSC) (5)Natalizumab (Tysabri) (4)Siponimod (Mayzent) (4)Remibrutinib (4)CAR-T cell therapy (4)Alemtuzumab (Lemtrada) (3)Glatiramer acetate (Copaxone) (3)Frexalimab (3)Metformin (3)Cannabis and cannabinoids (3)
